Pharma and healthcare: sector news on Wednesday 4 November 2026
Average tone +1.1 (neutral) across 5 companies with relevant coverage, from 50 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +5.0 | 19 | Coverage was mostly positive, with brokers reiterating Buy ratings, solid quarterly results with unchanged guidance, and a favourable Delhi High Court outcome in a pricing case. |
| GSK | +5.0 | 14 | Coverage was led by Canadian approval and priority review of GSK's hepatitis B drug bepirovirsen, plus an FDA approval for Benlysta and a proteomics research partnership. |
| Convatec | +1.8 | 10 | Coverage was dominated by Convatec naming Jill McConnell as its next chief financial officer to succeed Fiona Ryder. |
| Smith & Nephew | −1.7 | 4 | Coverage centred on an upcoming trading update and a recent cartilage implant launch, alongside a Breakingviews column arguing the company needs bolder restructuring. |
| Haleon | −4.5 | 3 | Coverage centred on a weaker outlook for Haleon's shares after a slowdown in the third quarter, along with a lower analyst price target that still implies upside. |
Strongest stories in the sector
- +10.0 Approval of new hepatitis B therapy, a significant milestone
- +10.0 Fast-track regulatory review for promising hepatitis B drug in Canada
- +8.3 Won court relief in pricing overcharge dispute in India.
- +8.3 Favourable court outcome in inhaler pricing case.
- +7.5 Shares continuing to rise after latest quarterly figures.
- +7.5 Regulatory approval of a cancer drug expected to support market growth.
- +7.5 Regulatory clearance for an existing GSK lupus medicine
- −7.0 Share outlook described as weak following slower third-quarter performance.
- +6.7 Broker maintains positive recommendation.
- −6.7 Vaccine death case with legal pressure to negotiate with family.
- +6.7 Major bank repeats positive recommendation.
- +6.7 Another broker repeats positive recommendation.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.